Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

An-Liang Xia, Xiao-Chen Wang, Yi-Jun Lu, Xiao-Jie Lu and Beicheng Sun _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:90521-90531. https://doi.org/10.18632/oncotarget.19361

Metrics: PDF 5125 views  |   HTML 8316 views  |   ?  


An-Liang Xia1,*, Xiao-Chen Wang1,*, Yi-Jun Lu1*, Xiao-Jie Lu1 and Beicheng Sun1

1 Liver Transplantation Center of the First Affiliated Hospital and Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu Province 210029, P.R. China

* Co-first authors

Correspondence to:

Beicheng Sun, email:

Xiao-Jie Lu, email:

Keywords: chimeric antigen receptor, T cells, cancer, adoptive cell transfer, tumor microenvironment

Received: April 12, 2017 Accepted: June 18, 2017 Published: July 18, 2017


Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for solid tumors currently is faced with numerous challenges such as physical barriers, the immunosuppressive tumor microenvironment and the specificity and safety. The clinical results in solid tumors have been much less encouraging, with multiple cases of toxicity and a lack of therapeutic response. In this review, we will discuss the current stats and challenges of CAR-T cell therapy for solid tumors, and propose possible solutions and future perspectives.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19361